[Immune thrombocytopenia: From pathogenesis to treatment].
Fiche publication
Date publication
juillet 2020
Journal
La Revue de medecine interne
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard
Tous les auteurs :
Audia S, Mahevas M, Bonnotte B
Lien Pubmed
Résumé
Immune thrombocytopenia (ITP) is a rare autoimmune disease due to an immune peripheral destruction of platelets and an inappropriate platelet production. The pathogenesis of ITP is now better understood: it involves a humoral immune response which dependents on the stimulation of B cells by specific T cells called T follicular helper cells, leading to their differentiation into plasma cells that produce antiplatelet antibodies thus promoting the phagocytosis of platelets mainly by splenic macrophages. The deciphering of ITP pathogenesis has led to a better understanding of the inefficiency of treatments such as rituximab, although it has not provided yet the determination of biological predictive factor of response to treatments. Moreover, new therapeutic perspectives have been opened in the last few years with the development of molecules targeting Fcγ receptor signalling such as Syk inhibitor, or molecules increasing the clearance of pathogenic autoantibodies such as inhibitors of the neonatal Fc receptor (FcRn).
Mots clés
Immune thrombocytopenia, Pathogenesis, Physiopathologie, Purpura thrombopénique immunologique, Thrombopénie immunologique, Traitements, Treatment
Référence
Rev Med Interne. 2020 Jul 30;: